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Abstract: Background: Revascularization strategies for chronic mesenteric ischemia (CMI) include open
(OR) and endovascular (ER) modalities. The primary objective of this study was to analyze the safety and
effectiveness of OR and ER and the impact of clinical and morphological variables on early and midterm
outcomes in a consecutive series of CMI patients in a tertiary referral center. Patients and methods:
From 2004 to 2017, all CMI patients treated with OR and ER were retrospectively identified. Patient
records, preoperative imaging, as well as peri- and postoperative outcomes were analyzed. Univariable and
multivariable analysis was performed to identify clinical or morphological variables affecting reintervention
rates within 2 years. Results: In total, 63 patients (33% male; mean age 71, range 60-76 years) were
treated by ER (41 patients) or OR (22 patients) for CMI. Mean follow-up was 26 (10-71) months. 30-day
mortality was 0.0% after ER and 4.5% after OR (p = 0.069); 30-day morbidity was 9.8% vs. 31.8%,
respectively (p = 0.030). Length of stay was significantly longer after OR (14 vs. 4 days; p < 0.001).
Freedom from reintervention rate after 2 years was 82% after OR and 73% after ER (p = 0.14). Overall
survival did not differ after 2 years (OR 85% vs. ER 86%; p = 0.35). Multivariable analysis revealed
that smoking was associated with higher risk of reintervention (hazard ratio, HR: 4.14; 95% confidence
interval, CI 1.11-15.53; p = 0.03). Additionally, a nonsignificant trend of lower reintervention rates after
OR was detected (HR 0.23 95% CI 0.05-1.08; p = 0.06). Conclusion: Due to a lower invasiveness, despite
the higher reintervention rate, an ”endovascular first” strategy is justified and recommended.
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Abstract
Background Revascularization strategies for chronic mesenteric ischemia (CMI) include open (OR) and endovas-
cular (ER) modalities. The primary objective of this study was to analyze the safety and effectiveness of OR and ER
and the impact of clinical and morphological variables on early and midterm outcomes in a consecutive series of CMI
patients in a tertiary referral center.
Patients and methods From 2004 to 2017, all CMI patients treated with OR and ER were retrospectively identified.
Patient records, preoperative imaging, as well as peri- and postoperative outcomes were analyzed. Univariable and
multivariable analysis was performed to identify clinical or morphological variables affecting reintervention rates
within 2 years.
Results In total, 63 patients (33% male; mean age 71, range 60–76 years) were treated by ER (41 patients) or OR
(22 patients) for CMI. Mean follow-up was 26 (10–71) months. 30-day mortality was 0.0% after ER and 4.5% after
OR (p = 0.069); 30-day morbidity was 9.8% vs. 31.8%, respectively (p = 0.030). Length of stay was significantly
longer after OR (14 vs. 4 days; p\ 0.001). Freedom from reintervention rate after 2 years was 82% after OR and
73% after ER (p = 0.14). Overall survival did not differ after 2 years (OR 85% vs. ER 86%; p = 0.35). Multivariable
analysis revealed that smoking was associated with higher risk of reintervention (hazard ratio, HR: 4.14; 95%
confidence interval, CI 1.11–15.53; p = 0.03). Additionally, a nonsignificant trend of lower reintervention rates after
OR was detected (HR 0.23 95% CI 0.05–1.08; p = 0.06).
Conclusion Due to a lower invasiveness, despite the higher reintervention rate, an ‘‘endovascular first’’ strategy is
justified and recommended.
Introduction
Although the prevalence of severe atherosclerosis of the
mesenteric arteries supposedly ranges between 30 and 50%
in the elderly population ([ 65 years), the exact incidence
of chronic mesenteric ischemia (CMI) is unknown. Clini-
cally, CMI is a rarely diagnosed cause of abdominal pain
[1, 2]. Scott J. Boley, a pioneer in the field of mesenteric
ischemia, has been studying mesenteric circulation and
vascular disorders of the intestines since the early 1960s. A
particular concern was to focus physicians’ attention on the
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methods for, and potential success of, early diagnosis and
aggressive treatment of these conditions [3, 4].
In approximately 90% of patients, it is caused by an
atherosclerotic stenosis or occlusion of the superior
mesenteric artery (SMA) and/or the celiac trunk (CTr)
[5, 6]. Stenoses or occlusions of the inferior mesenteric
artery (IMA) are usually clinically silent.
The most characteristic symptoms are postprandial
abdominal pain, ‘‘food fear,’’ and subsequent unintended
weight loss. However, patients can also present with non-
specific symptoms such as malaise, appetite loss, nausea,
diarrhea, and weight loss of unclear origin [7]. The correct
diagnosis is often made only after several months and,
consequently, the majority of cases are recognized in late
stages [8]. Persistent and refractory complaints are an
indicator of advanced stage with chronic mesenteric
malperfusion. Due to a vast collateral network of mesen-
teric vessels, symptoms usually only occur if more than one
artery is affected. This is in contrast to acute mesenteric
ischemia (AMI), where embolic occlusion of the SMA
usually constitutes a life-threatening situation [9].
Revascularization has been proven to be beneficial in
cases of symptomatic CMI, regardless of the number of
affected vessels [10]. Additionally, invasive treatment can
be indicated in selected cases of non-symptomatic
atherosclerotic mesenteric arteries, to prevent AMI in the
further course [11].
While computed tomography angiography (CTA) is the
diagnostic method of choice, the optimal revascularization
strategy for individual patients sometimes remains unclear
[12].
The first successful open revascularization (OR) for
CMI was reported in 1958 by RS Shaw from the Mas-
sachusetts General Hospital when performing endarterec-
tomy of the SMA [13]. Due to the rapid development of
endovascular techniques and the assumed lower procedural
morbidity and mortality compared to OR [14–16], the
therapeutic approach has progressively moved from open
repair (OR) to a primary endovascular approach. ER is now
applied initially in 70–80% cases [15, 17].
Since randomized controlled trials (RCTs) comparing
OR and ER are lacking, the primary objective of this study
was to examine early and midterm outcomes in a consec-
utive series of CMI patients treated by OR and ER at a
tertiary referral center. In particular, clinical and morpho-
logical variables and their potential impact on reinterven-
tion rates and long-term survival were analyzed.
Patients and methods
This study is a retrospective analysis of a consecutively
treated cohort of CMI patients at a single university hos-
pital center between January 2004 and December 2017.
Identification of the study patients was based on the hos-
pital information system that includes all medical records.
Patients were retrieved using the German modification of
the International Classification of Diseases (ICD)-10 code
for CMI (K55.1). Inclusion criteria were surgical or
endovascular treatment of CMI. Patients who required
additional surgical treatment (e.g., for concurrent aortic
aneurysm repair or renal revascularization) and patients
with acute mesenteric ischemia (AMI) were excluded.
Diagnostic and surgical strategies
All patients underwent CTA to assess individual anatomy
and determine the feasibility of an endovascular approach.
All CTAs were evaluated by an interdisciplinary vascular
board (vascular surgery, radiology, and cardiology) for
different therapeutic strategies. The choice of therapy was
affected by anatomy, comorbidities, the urgency of repair,
and the patient’s preference. ER was performed by per-
cutaneous transluminal angioplasty (PTA) and/or stenting
of one or more visceral vessels under local anesthesia
whenever possible. OR was performed by transposition of
the SMA (or IMA in one patient) into the aorta, bypass
grafting, or endarterectomy.
Data acquisition
Baseline clinical data included sex, age, clinical presenta-
tion (postprandial abdominal pain, weight loss, diarrhea,
and duration of abdominal complaints), surgical and
medical history, and comorbidities. Specific data included
the number of affected mesenteric arteries, surgical strat-
egy, primary technical success, length of stay (LoS),
complications (cardiac, respiratory, renal, gastrointestinal,
wound healing, and puncture site complications), and
reintervention rates. Morphological data included type,
length, location of lesion, previous interventions, and grade
of calcification as described by Zacharias et al. [18]. For
calcification scoring, two experienced readers separately
evaluated the CTA data. Disagreements were solved by
consensus. The circumference of the affected vessel was
divided into thirds and classified into low-, middle-, and
high-grade calcification, similar to methods reliably used in
the coronary or carotid arteries [19]. Technical success was
defined as residual stenosis of less than 30% by
angiography.
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Data acquisition was in accordance with the Declaration
of Helsinki and written informed consent was obtained
from all patients.
Follow-up was carried out in accordance with a stan-
dardized protocol and included a clinical examination and
duplex ultrasound of the visceral arteries 6 weeks after
discharge and annually thereafter in an outpatient setting.
Patients with recurrent symptoms were additionally eval-
uated with CTA or diagnostic angiography. If not seen
within the standard surveillance protocol, patients or their
family doctors were contacted by phone and an appoint-
ment was made for the patient for a follow-up evaluation at
the time of data collection in March 2018.
Endpoints
Primary endpoints were 30-day mortality (safety endpoint)
and freedom from reintervention (efficacy endpoint). Sec-
ondary endpoints were perioperative (30-day) morbidity,
LoS, and overall survival (OS).
Technical success in the case of ER was defined as
residual stenosis of less than 30%, confirmed at the end of
the endovascular procedure. In OR cases, technical success
was characterized by patent reconstruction of the visceral
arteries. Clinical success was defined as resolution of
clinical symptoms within 3 days after OR or ER. Medical
complications within the first 30 days postoperatively
defined 30-day morbidity, whereby we differentiated
between seven groups of complications.
Statistics
Categorical data were compared using Fisher’s exact and
Chi-square tests, and continuous data were assessed by the
Mann–Whitney U test. Primary patency and survival rates
were estimated using Kaplan–Meier analysis and compared
with a log-rank test. Univariable and multivariable analysis
on demographic, clinical, and morphological characteris-
tics was performed to assess their association with the risk
of reintervention. For the primary safety and efficacy
endpoints, a baseline Cox proportional hazards model was
fitted using demographic variables (age and sex) only.
Subsequently, another clinical or morphological variable
was added to the baseline model, evaluated, and finally
removed again. Statistical analyses were performed using
Med-Calc version 9.6.4.0 (MedCalc Software, Mariak-
erke, Belgium), with p B 0.05 considered statistically
significant.
Results
Patient characteristics (Table 1)
A total of 63 patients (33% male; mean age 71, range
60–76 years) fulfilled the inclusion criteria. Over the study
period, an increasing number of patients (2002 n = 2, 2017
n = 8) were treated with ER.
Main clinical symptoms were abdominal angina and
weight loss, found in 84 and 60%, of patients, respectively.
Atherosclerotic risk factors, comorbidities, and patient
demographics were quite evenly distributed between the
OR and ER groups. Most patients (87%) had no prior
surgical or endovascular intervention of the mesenteric
arteries. However, the majority (80%) had already been
treated for atherosclerotic diseases in another vascular
region.
Morphological variables (Table 1)
Of all patients, 60% suffered from multivessel disease. In
89% of patients, the SMA was affected. Whereas the cal-
cification grade did not differ between OR and ER, sig-
nificantly more occlusions were treated in the OR group
(32 vs. 10%, p = 0.030).
Surgical treatment (Table 2)
ER was used in 41 patients (45 arteries) and OR in
22 patients (24 arteries) and was performed by angioplasty
alone in 17/41 patients (17 arteries). An additional stent
was used in 24/41 patients (24 arteries). The most common
procedure in the OR group was transposition of the SMA in
the aorta or aortomesenteric bypass surgery (14/22 pa-
tients). In both groups, usually only one visceral artery was
treated (OR 80% vs. ER 86%). The technical success rate
was 88% in the ER group and 100% in the OR group. Two
patients had to be converted to OR after failed ER within
7 days. Further, they were considered to OR group.
Early outcomes (Table 2)
Mortality (30-day and in-hospital) was 1.6% (0% for ER;
4.5% for OR; p = 0.069), with one fatality on day 12 due
to necrotizing pancreatitis. A total of 11 patients (17.5%)
suffered from perioperative complications (30-day mor-
bidity), with significantly higher numbers in the OR group
as compared to ER (31.8% vs. 9.8%; p = 0.030).
There were mild complications in the ER group in three
cases (angina pectoris (n = 1), ischemic rectitis (n = 1) and
one false aneurysm in the femoral puncture site (n = 1))
and severe complications in one case (pneumonia and
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urosepsis). In the OR group, five of seven patients had
severe complications (myocardial infarction (n = 2),
pneumonia (n = 1), acute renal failure (n = 1), pancreatic
fistula (n = 1), and pancreatitis (n = 1)) and two mild
complications (postoperative delirium, deep vein
thrombosis).
LoS was longer after OR compared to ER (14, Q1–Q3:
10–17 vs. 4:Q1–Q33–7 days, p\ 0.001).
The freedom from reintervention rates at 30 days was
96% vs. 97% after OR and ER, respectively (p = 0.069).
Midterm and late outcomes (Tables 2, 3)
Clinical success was achieved in 95% in both groups. The
remaining 5% had persistent complaints despite technical
success; initial misdiagnosis thus had to be considered, and
patients were transferred to the gastroenterology
department.
Mean follow-up was 26 (Q1–Q3: 10–71) months.
Longer follow-up was available in 18 patients (28.5%). In
Kaplan–Meier analysis freedom from reintervention rates
within 2 years were 82% for OR and 73% for ER
(p = 0.14). Recurrent stenosis with or without symptoms
indicated reintervention.
There was also no significant difference between OR
and ER in Kaplan–Meier analysis for OS, with 30-day and
2-year survival rates of 95 and 85% for OR, and 100 and
86% for ER, respectively (p = 0.35).
In the uni- and multivariable analysis (Table 3, Fig. 1)
adjusted for clinical and morphological parameters, a
positive smoking history or current smoking was associated
with a significantly higher risk of reintervention (hazard
ratio, HR: 4.14; 95% confidence interval, CI 1.11–15.53;
p = 0.03; Fig. 1), while OR tends toward a lower reinter-
vention risk (HR 0.23, 95% CI 0.05–1.08; p = 0.06).
Table 1 Patient demographics, comorbidities, and morphological criteria
Total (n = 63) ER (n = 41) OR (n = 22)a p value
Demographics
Age (years) median (range) 71 (60–76) 71 (64–78) 70 (53–73) 0.145
Sex (male%) 21 (33.3) 11 (26.8) 10 (45.5) 0.137
Symptoms
Weight loss 38 (60.3) 22 (53.7) 16 (72.7) 0.145
Postprandial pain 53 (84.1) 36 (87.8) 17(77.3) 0.281
Nausea and vomiting 12 (19.0) 7 (17.1) 5 (22.7) 0.593
Diarrhea 15 (23.8) 12 (29.3) 3 (13.6) 0.167
Symptom onset (months), median (range) 3 (0.5–11) 5 (0.5–14) 2 (0.6–6) 0.165
Comorbidities
Hypertension 40 (63.5) 27 (65.9) 13 (59.1) 0.596
Hyperlipidemia 25 (39.7) 17(41.5) 8(36.4) 0.696
CHD 25 (39.7) 18 (43.9) 7 (31.8) 0.353
Ever smoker 31 (49.2) 21 (51.2) 10 (45.5) 0.669
Diabetes 20 (31.7) 13 (31.7) 7 (31.8) 0.994
ESRD 7 (11.1) 4 (9.8) 3 (13.6) 0.650
Morphological parameter
High-grade calcification 36 (57.1) 23 (56.1) 13 (59.1) 0.820
Middle-grade calcification 8 (12.7) 5 (12.2) 3 (13.6) 0.875
Low-grade calcification 18 (28.6) 13 (31.7) 5 (22.7) 0.455
Location of vessel occlusion[ 2 cm from origin 15 (23.8) 9 (22.0) 6 (27.3) 0.641
Length of stenosis[ 2 cm 9 (14.3) 4 (9.8) 5 (22.7) 0.167
Occlusion 11 (17.5) 4 (9.8) 7 (31.8) 0.030
Previous interventions 8 (12.7) 6 (14.6) 2 (9.1) 0.535
When not stated otherwise, results are given as numbers (%)
ER endovascular repair, OR open repair, CHD coronary heart disease, ESRD end-stage renal disease
a2 patients were converted after failed ER within 7 days and further considered as OR
p values were calculated by Mann–Whitney U or Chi-square tests, significant difference is highlighted in bold
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Table 2 Technical details and comparison of 30-day peri- and postoperative outcomes for open (OR) and endovascular repair (ER) of chronic
mesenteric ischemia
Total (n = 63) ER (n = 41) OR (n = 22) p value
Technical procedures
Number of artery (n) 69 45 24 N/A
Angioplasty – 17 (18) – N/A
Stenting – 24 (27) – N/A
Failure of endovascular therapy – 2 (2) – N/A
Endarterectomy – – 5 (7) N/A
Mesenteric bypass or transposition – – 14 (14) N/A
Thrombectomy – – 1 (1) N/A
Resection of arcuate ligament – – 2 (2) N/A
Early outcome
30-day morbidity 11 (17.5) 4 (9.8) 7 (31.8) 0.030
30-day freedom from reintervention 96.7% (92.4–100) 97.4% (92.6–100) 95.5% (87.1–100) 0.069
30-day mortality 1.6% (0 – 4.8) 0% (0–0) 4.5% (0–2.9) 0.768
Length of stay (days) 7 (3–12.5) 4 (3–7) 14 (10–17) < 0.001
Numbers represent median and range (Q1–Q3); technical details are given in number of patients n (number of arteries n); p values were
calculated by Mann–Whitney U or Chi-square test, significant differences are highlighted in bold
Table 3 Univariable analysis of clinical, morphological, and operative variables and their impact on the 2-year rates of reintervention after
endovascular or open revascularization for chronic mesenteric ischemia
HR(95% CI) p value
Baseline characteristics
Age C65 versus\65 years 0.64 (0.21–1.90) 0.42
Female/male 1.50 (0.49–4.60) 0.48
Clinical parameter
Hypertension (yes/no) 1.67 (0.51–5.44) 0.39
Hyperlipidemia (yes/no) 1.32 (0.44–3.93) 0.62
CHD (yes/no) 1.87 (0.63–5.57) 0.26
Ever smoker (yes/no) 3.91 (1.08–14.23) 0.04
Diabetes (yes/no) 2.46 (0.82–7.35) 0.11
ESRD (yes/no) 1.52 (0.34–6.88) 0.58
Morphological parameter
High-grade versus low-/mid-grade calcification 1.15 (0.39–3.45) 0.80
Stenosis/occlusion[2 cm versus\2 cm from origin 1.07 (0.29–3.90) 0.92
Lesion length[2 cm/\2 cm 1.67 (0.46–6.10) 0.44
Occlusion versus stenosis 1.16 (0.32–4.23) 0.82
Previous interventions (yes/no) 1.84 (0.51–6.68) 0.36
Mode of revascularization
OR versus ER 0.27 (0.06–1.23) 0.09
HR hazard ratio, CI confidence interval, OR open revascularization, ER endovascular revascularization, CHD coronary heart disease, ESRD end-
stage renal disease
P values were calculated by Mann–Whitney U or Chi-square tests, significant differences are highlighted
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Discussion
In this consecutive cohort of patients suffering from
chronic mesenteric ischemia (CMI), there were no signif-
icant differences in terms of reintervention rate, 30-day
mortality, or overall survival (OS) between endovascular
(ER) or open vascular surgical revascularization (OR)
during a mean follow-up of 26 months. As with many other
studies in the field, most likely due to the small sample
number, we only observed trends for a lower reintervention
rate in OR and better OS in ER. OR was associated with a
higher rate of 30-day morbidity and longer LoS. In mul-
tivariable analysis, smoking history was associated with
higher rates of reintervention.
As in other studies, a significant higher perioperative
morbidity for OR in our cohort was observed, while there
was no significant difference between ER and OR in terms
of 30-day mortality (Table 2) [20]. Overall, 30-day mor-
tality in the OR group was 4.5% and thus almost identical
to the 5.5% of a recently published meta-analysis [21].
However, perioperative mortality due to cardiovascular
events can be as high as 15% after OR [22]. In our
department, a complete preoperative cardiologic workup
including possible noninvasive imaging in all elective
patients precedes treatment.
However, due to the lower invasiveness of ER, there are
not only differences in perioperative morbidity, but also in
LoS. These results have been confirmed in various other
studies [20, 22, 23]. In addition, lower costs could be
calculated for ER compared to OR [24, 25].
Attention should be paid to the fact that not all lesions in
our cohort are suitable for ER, because of long-distance
occlusions. In our study, seven patients who were primarily
treated with OR would not have been eligible for an
endovascular procedure, which may well have led to a bias
in favor of ER.
One of the main problems of endovascular treatment in
general is its durability, mostly in terms of target vessel
patency [26]. Some of the newer methods (e.g., drug
eluting balloons or stents) are not yet used in clinical
routine for treating mesenteric vessels. However, although
freedom from reintervention showed no significant differ-
ence between ER and OR in our study, 30-day and 2-year
freedom from reintervention showed a tendency toward
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Fig. 1 Clinical, morphological parameters and mode of revascularization were adjusted for age and sex. HR, hazard ratio; CI, confidence
interval; OR, open revascularization; ER, endovascular revascularization, CHD, coronary heart disease, ESRD, end-stage renal disease
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favoring OR (albeit without statistical correction for vari-
ous endovascular means applied). This is likely due to the
low case number, and those patients lost to follow-up.
Another reason for the high reintervention rate could be the
treatment without stenting. In our study, nearly half of the
ER group (17 of 41 patients) was treated with angioplasty
alone. Prospective trials to compare angioplasty with pri-
mary stenting are missing. But experts agree, and the 2017
Guidelines from the European Society for Vascular Sur-
gery (ESVS) recommend that primary mesenteric stenting
is indicated [9, 27–30].
Nevertheless, the reintervention rate of 27% by ER after
2 years is in accordance with the published results [20, 31].
Therefore, reintervention rates and worse primary patency
rates need to be considered when opting for an ‘‘endo-first’’
strategy [22, 32].
Moreover, the multivariable analysis of the current
study confirmed a tendency of lower reintervention rates
for OR. Thus, OR remains a viable option in patients who
are fit for surgery and are morphologically no good can-
didates for ER. Particularly, an early change of regimen
after failed ER should be considered as supported by the
ESVS guidelines [9].
Decision-making should also support clinical or mor-
phological variables which might be associated with lower
patency rates [33]. Even though the numbers of CMI
patients were relatively low in this study, our multivariable
analysis revealed that patients with a history of smoking or
current smoking have a fourfold higher risk of reinter-
vention. This seems plausible, since although hit has not
been described for mesenteric arteries, other investigations
of different areas and techniques have reported similar
results regarding smoking as a risk factor for restenosis
[34–38]. Regarding the complexity of lesions, Oderich
et al. investigated endovascular procedures. In this study,
female sex as well as long (\ 20 mm) and calcified lesions
significantly increased the risk of in-stent restenosis
[31, 39]. These factors were also analyzed in our cohort,
but did not show the significant results due to the small
sample size (Table 3).
Not only the high rate of reintervention plays an
important role in arteriosclerotic disease, but also the poor
overall survival has (OS) [40]. Patients with severe
atherosclerotic burden have a poor survival prognosis; for
example, patients with chronic limb threatening ischemia
have a 1-year survival probability of only about 75% if
affected by CMI [41]. However, even patients with CMI
alone have a poor OS [42]. Therefore, it is satisfying that
OS in this study was 98.4% at 30 days and 86.1% at
2 years. We were not able to detect any difference between
the two treatment options, and these results thus correspond
to the results of the 2018 published meta-analysis, where
also no significant difference in the 3-year OS of 78% was
found.
Another treatment option that should be mentioned but
was not used in our cohort is a hybrid procedure with
retrograde stenting of SMA. This option may be selected
when transaortic stenting and open reconstruction are
impossible, e.g., in case of extensive aortoiliac disease and
no good source of inflow, and it is mainly recommended in
those with acute mesenteric ischemia. The use of a hybrid
approach provides one of the most expeditious methods of
revascularization in patients with difficult SMA occlusions
[9, 43–45].
Several shortcomings of this study need to be addressed.
First, selection bias is possible as it is a single-center
analysis. Second, the cardiovascular and morphological
risk factors used in the multivariate analysis represent only
a small number of the factors influencing OS and freedom
from reintervention. Finally, this study had the inherent
limitations of a retrospective analysis.
Conclusion
CMI is a rare disease that can be effectively treated by ER
and OR. ER tends to have higher rates of reintervention,
while 30-day morbidity is higher and hospital LoS is longer
in patients treated with OR. Due to the less invasive nature
of ER, the results support the ‘‘endovascular-first’’ strategy
that has been established in recent years.
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